The daily response for proton pump inhibitor treatment in Japanese reflux esophagitis and non-erosive reflux disease
- PMID: 23341702
- PMCID: PMC3541423
- DOI: 10.3164/jcbn.12-69
The daily response for proton pump inhibitor treatment in Japanese reflux esophagitis and non-erosive reflux disease
Abstract
We investigated comparison according to reflux esophagitis and non-erosive reflux disease about "daily" symptom improvement for proton pump inhibitor treatment. We enrolled 57 reflux esophagitis and 90 non-erosive reflux disease patients. They took rabeprazole 10 mg/day for 28 days and completed "daily" in the Frequency Scale for the Symptoms of GERD from baseline until day 14, and after 28 days of treatment. The efficacy endpoint was the improvement rates in Frequency Scale for the Symptoms of GERD, based on baseline. Frequency Scale for the Symptoms of GERD was decreased in reflux esophagitis and non-erosive reflux disease (p<0.001) and was significantly lower in reflux esophagitis than in non-erosive reflux disease from the first day of treatment (p<0.05). Symptomatic improvement rates were also significantly higher in reflux esophagitis (50.3 ± 44.9%) than in non-erosive reflux disease (31.7 ± 43.2%) from the first day of treatment (p<0.0001). The symptomatic improvement rates in reflux esophagitis were significant increased from the second day of treatment until after 28 days of treatment (p = 0.0006), however, these in non-erosive reflux disease were significant increased from third days until after 28 days of treatment (p = 0.0002). In non-erosive reflux disease, the improvement of dysmotility symptom was particularly gradual as well as of reflux symptom, too. As for results of prediction of proton pump inhibitor response (completed symptom resolution) form early symptom improvement within 1 week, it was able to predict proton pump inhibitor response from the symptom improvement rate on 3 days in reflux esophagitis and on day 7 in non-erosive reflux disease. In conclusion, the prediction of the proton pump inhibitor response in non-erosive reflux disease was slow in comparison with reflux esophagitis. The cause was gradual improvement of dysmotility symptom.
Keywords: endoscopy: upper GI; esophagus; gastroesophagus reflux disease; the frequency scale for the symptoms of GERD.
Figures




Similar articles
-
Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.Am J Gastroenterol. 2001 Oct;96(10):2849-57. doi: 10.1111/j.1572-0241.2001.4237_a.x. Am J Gastroenterol. 2001. PMID: 11695354 Clinical Trial.
-
Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis.Clin Gastroenterol Hepatol. 2015 May;13(5):859-66.e1. doi: 10.1016/j.cgh.2014.09.033. Epub 2014 Sep 20. Clin Gastroenterol Hepatol. 2015. PMID: 25245625 Clinical Trial.
-
Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.Dig Endosc. 2012 Nov;24(6):407-11. doi: 10.1111/j.1443-1661.2012.01301.x. Epub 2012 Apr 8. Dig Endosc. 2012. PMID: 23078431 Clinical Trial.
-
Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.J Gastroenterol. 2016 Aug;51(8):751-67. doi: 10.1007/s00535-016-1227-8. Epub 2016 Jun 21. J Gastroenterol. 2016. PMID: 27325300 Review.
-
Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux.Aliment Pharmacol Ther. 2006 Mar;23 Suppl 1:25-32. doi: 10.1111/j.1365-2036.2006.02802.x. Aliment Pharmacol Ther. 2006. PMID: 16483267 Review.
Cited by
-
Proton pump inhibitor for non-erosive reflux disease: a meta-analysis.World J Gastroenterol. 2013 Dec 7;19(45):8408-19. doi: 10.3748/wjg.v19.i45.8408. World J Gastroenterol. 2013. PMID: 24363534 Free PMC article. Review.
-
Increase of transient lower esophageal sphincter relaxation associated with cascade stomach.J Clin Biochem Nutr. 2017 May;60(3):211-215. doi: 10.3164/jcbn.16-53. Epub 2017 Apr 7. J Clin Biochem Nutr. 2017. PMID: 28584403 Free PMC article.
References
-
- Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol. 2009;44:518–534. - PubMed
-
- Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; The montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–1920. - PubMed
-
- The Japanese Society of Gastroenterology. GERD management guideline. Tokyo: Nankodo; 2009. pp. 54–61. (in Japanese)
-
- Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease—where next? Aliment Pharmacol Ther. 2005;22:79–94. - PubMed
-
- Talley NJ, Armstrong D, Junghard O, Wiklund I. Predictors of treatment response in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2006;24:371–376. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials